Global Healthcare Study on Psoriasis

NCT07634016 · tracked via the Priya Life Science Switzerland tracker

Sponsor

Julia Tatjana Maul

Phase

Observational

Started

2025-01-01

Last updated

2026-09-28

Condition(s) studied

Psoriasis (PsO)

Study summary

The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Eligibility

Sex

ALL

Min age

14 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Signed General Consent Form, or equivalent document * Confirmed diagnosis of Psoriasis Exclusion Criteria: * Inability to provide informed consent. * Datasets with ambiguous or unclear diagnosis.

Primary outcome measure(s)

Psoriasis Area Severity Index (PASI) — Baseline and follow-up visits every 6-12 months for up to 5 years.
Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.

Trial sites (1)

Facility	City	Region	Status
University of Zurich	Zurich	Switzerland	Recruiting

More Julia Tatjana Maul trials in Switzerland

Global Healthcare Study on Atopic Dermatitis Recruiting

Global Healthcare Study on Hidradenitis Suppurativa Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07634016 on ClinicalTrials.gov ↗ ← All trials in Switzerland